Analysts Expect Iovance Biotherapeutics Inc (NASDAQ:IOVA) to Post -$0.29 EPS

Share on StockTwits

Brokerages predict that Iovance Biotherapeutics Inc (NASDAQ:IOVA) will announce earnings per share (EPS) of ($0.29) for the current quarter, Zacks reports. Zero analysts have made estimates for Iovance Biotherapeutics’ earnings, with estimates ranging from ($0.34) to ($0.18). Iovance Biotherapeutics reported earnings per share of ($0.34) in the same quarter last year, which suggests a positive year-over-year growth rate of 14.7%. The firm is expected to announce its next earnings report on Monday, August 5th.

According to Zacks, analysts expect that Iovance Biotherapeutics will report full year earnings of ($1.19) per share for the current fiscal year, with EPS estimates ranging from ($1.44) to ($0.84). For the next year, analysts anticipate that the business will post earnings of ($1.39) per share, with EPS estimates ranging from ($1.99) to ($0.59). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover Iovance Biotherapeutics.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.01).

A number of equities analysts have recently commented on the stock. HC Wainwright set a $10.00 target price on shares of Jaguar Health and gave the company a “buy” rating in a research note on Tuesday, July 2nd. Oppenheimer set a $32.00 target price on shares of Iovance Biotherapeutics and gave the company a “buy” rating in a research note on Wednesday, July 3rd. BidaskClub lowered shares of Zebra Technologies from a “hold” rating to a “sell” rating in a research note on Friday, May 24th. ValuEngine lowered shares of Verso from a “hold” rating to a “sell” rating in a research note on Thursday, May 23rd. Finally, B. Riley set a $2.00 price target on shares of Ascena Retail Group and gave the stock a “hold” rating in a research report on Friday, May 17th. One analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $28.45.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Advisor Group Inc. grew its position in Iovance Biotherapeutics by 58.6% during the fourth quarter. Advisor Group Inc. now owns 8,118 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 3,000 shares in the last quarter. Virtu Financial LLC purchased a new position in Iovance Biotherapeutics during the first quarter valued at approximately $99,000. Great West Life Assurance Co. Can grew its position in Iovance Biotherapeutics by 67.4% during the fourth quarter. Great West Life Assurance Co. Can now owns 14,538 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 5,853 shares in the last quarter. Moors & Cabot Inc. purchased a new position in Iovance Biotherapeutics during the first quarter valued at approximately $126,000. Finally, Amalgamated Bank purchased a new position in Iovance Biotherapeutics during the fourth quarter valued at approximately $130,000. Institutional investors and hedge funds own 94.97% of the company’s stock.

Shares of IOVA stock traded up $0.05 during trading hours on Tuesday, hitting $26.00. The company’s stock had a trading volume of 837,600 shares, compared to its average volume of 1,461,065. The stock has a fifty day moving average of $22.35. The firm has a market capitalization of $3.15 billion, a PE ratio of -20.47 and a beta of 1.77. Iovance Biotherapeutics has a twelve month low of $7.26 and a twelve month high of $26.59. The company has a current ratio of 20.09, a quick ratio of 20.09 and a debt-to-equity ratio of 0.01.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

See Also: Blockchain

Get a free copy of the Zacks research report on Iovance Biotherapeutics (IOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.